Treatment Methodology for the Prevention and Control of Viral Infections

Abstract

A treatment methodology for the prevention and control of viral infections by administering an anti-viral composition having organotrophic archaea microorganisms, a carrier substance and an activating liquid, characterized in that the archaea microorganisms, when present in human or animal, weaken or destroy a virus upon contact. The anti-viral composition is administered either intraorally or intranasally.

Claims

1. A method of preventing and controlling viral infections in humans or animals comprising the steps of: providing an anti-viral composition comprising organotrophic archaea microorganisms, a carrier substance and an activating liquid, characterized in that the archaea microorganisms, when present in a human or animal, weaken or destroy a virus upon contact; administering the anti-viral composition to the human or animal in efficacious amount whereby viruses entering the human or animal come into contact with the anti-viral composition and are weakened or destroyed.

2. The method of claim 1, wherein the archaea microorganisms consist of different types of archaea microorganisms.

3. The method of claim 1, wherein the archaea microorganisms consist of at least 100 different types of archaea microorganisms.

4. The method of claim 1, wherein the carrier substance consists of sugar or bentonite clay.

5. The method of claim 1, wherein the activating liquid is water.

6. The method of claim 1, wherein the concentration of archaea microorganisms present in the combination of the archaea microorganisms and the carrier substance is from 2 to 100 billion per gram.

7. The method of claim 1, wherein the step of administering the anti-viral composition to the human or animal is accomplished intraorally or intranasally.

8. The method of claim 7, wherein the composition is swallowed.

9. The method of claim 7, wherein the composition is sprayed into nostrils.

10. The method of claim 7, wherein the composition is swabbed in nostrils.

11. The method of claim 1, wherein the step of administering the composition is repeated periodically.

12. The method of claim 3, wherein the concentration of archaea microorganisms present in the combination of the archaea microorganisms and the carrier substance is from 2 to 100 billion per gram.

13. The method of claim 12, wherein the step of administering the anti-viral composition to the human or animal is accomplished intraorally or intranasally.

14. The method of claim 4, wherein the concentration of archaea microorganisms present in the combination of the archaea microorganisms and the carrier substance is from 2 to 100 billion per gram.

15. The method of claim 14, wherein the step of administering the anti-viral composition to the human or animal is accomplished intraorally or intranasally.

16. The method of claim 15, wherein the archaea microorganisms consist of at least 100 different types of archaea microorganisms.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0014] The invention is in general a treatment method to prevent and control viral infections in humans and animals though administration of an anti-viral composition containing nonpathogenic archaea, more preferably a combination of different archaea microorganisms, and most preferably a combination of approximately 100 different archaea microorganisms. The composition is administered to an animal or human by oral ingestion, inhalation, spraying into the nostrils, or coating the interior of the nostrils in order to prevent, control and eradicate viral infections by attacking the invading virus, such as infections caused by Covid19, HIV, influenza or the like. All or most of the archaea microorganisms in the composition are organotrophic.

[0015] Common viruses that are detrimental to humans or animals include influenza, the Human Immunodeficiency Virus (HIV), or the Novel Coronavirus (SARS-CoV-2), commonly referred to as Covid19. For ease of reference, the composition and methodology is discussed herein with reference to Covid19, but such targeted referencing is not meant to limit or restrict the viruses against which the composition and methodology may be utilized.

[0016] Covid19 is an enveloped virus, having a protective layer of sugar, fat, and lipids which helps to not only protect the virus and hide the virus from the human immune system, but also aids in its pathogenic properties once in the human body. The Covid19's fatty shield has spikes that are coated in sugars, known as glycans. These characteristics form the focus of the inventive methodology, which utilizes organotrophic archaea that feed on particular organic substances, to wit, sugar, fat and or lipids, to neutralize, weaken or eradicate the Covid19, thereby controlling or preventing viral infections in humans or animals.

[0017] A single organotrophic archaea microorganism, a combination of multiple organotrophic archaea microorganisms of different type, or most preferably, approximately at least 100 organotrophic archaea microorganisms of different type are combined with a carrier substance, such as powdered sugar or an ingestible clay, such as bentonite clay, with this mixture then combined with an activating liquid having a relatively neutral pH, such as water.

[0018] The archaea microorganisms are combined with or applied to the solid carrier substance to produce a mixture having billions of archaea microorganisms per gram. The mixture is mixed with an activator liquid, such as water. The composition is delivered to an animal or human by ingestion in liquid or solid form, or by inhalation, swabbing or spraying into the nostrils.

[0019] A representative and suitable product comprising the mixture of archaea and a carrier substance is available under the tradename ULTRA-ARCHAEA as sold by Ultratech International, Inc. of Jacksonville, Fla. This product in various mixtures contains from 5 to 90 billion archaea microorganisms per gram. The carrier substance is approximately 85% bentonite clay (a type of smectite clay formed through volcanic activity) and approximately 15% non-active, non-hazardous trace compounds, nutrients and other minerals (e.g., quartz, Cristobalite).

[0020] As a non-limiting example, from 0.5 to 5.0 grams of organotrophic archaea microorganisms is mixed with the carrier substance, most preferably a sugar or clay substance, the resulting mixture having approximately at least 1 billion archaea per gram, with a most preferred range being from 90-100 billion archaea per gram. The mixture is then combined with 25-100 ml of non-chlorinated water to create the composition. This composition is then brought into contact with the virus is various ways, such as intraorally or intranasally.

[0021] The composition may be ingested orally by swallowing the composition in liquid form prepared as previously discussed. The archaea and carrier substance may be pressed to form a compact body in pill or tablet form and swallowed along with water. The composition in powdered form may be sprinkled onto food and consumed. The liquid composition may be taken intranasally by snorting or spraying the composition into the nostrils or coating the nostrils with the composition using a swab or similar member. The composition could also be applied directly to a mask, thereby attacking the viruses on contact and providing a mechanism for inhalation of the composition throughout the period that the mask is worn.

[0022] Thus, the invention in various embodiments is a method of preventing and controlling viral infections in humans or animals comprising the steps of: providing an anti-viral composition comprising organotrophic archaea microorganisms, a carrier substance and an activating liquid, characterized in that the archaea microorganisms, when present in a human or animal, weaken or destroy a virus upon contact; administering the anti-viral composition to the human or animal in efficacious amount whereby viruses entering the human or animal come into contact with the anti-viral composition and are weakened or destroyed. Furthermore, the invention comprises such a method wherein the archaea microorganisms consist of different types of archaea microorganisms; wherein the archaea microorganisms consist of at least 100 different types of archaea microorganisms; wherein the carrier substance consists of sugar or bentonite clay; wherein the activating liquid is water; wherein the concentration of archaea microorganisms present in the combination of the archaea microorganisms and the carrier substance is from 2 to 100 billion per gram; wherein the step of administering the anti-viral composition to the human or animal is accomplished intraorally or intranasally; wherein the composition is swallowed; wherein the composition is sprayed into nostrils; wherein the composition is swabbed in nostrils; and/or wherein the step of administering the composition is repeated periodically.

[0023] In addition to delivering the archaea composition directly to a human or animal, it could be added to soapy water and detergents prior to using on hard surfaces to attack viruses on those surfaces.

[0024] It is believed that single or combinations of organotrophic archaea consume or diminish the protective fatty barrier layer of the virus, as they are adept consumers of sugars, fats, and lipids in all settings. By doing so, the archaea composition destroys the virus or weakens the protective layer of the virus, allowing it to more easily be attacked and neutralized from the body via medication or anti-bodies, both natural or synthetic.

[0025] The composition can be provided in the form of and used as both a preventative medicine and treatment medicine. For instance, the composition could be dosed once every three to six weeks on a regular basis as a preventative. Alternatively, or in addition to, the composition could be dosed prior to or immediately after possible exposure to a virus, such as would be more likely to occur in large gatherings, during air travel, etc.

[0026] It is understood that equivalents and substitutions for certain elements and steps described above may be obvious to those of skill in the art, and therefore the scope and definition of the invention is to be as set forth in the following claims.